CD8A and neoplasm: As measured on day 13, BIBN4096 (5 mg kg−1, i.p., every other day) reduced B16F10 growth, tumour weight and frequency of PD-1+LAG3+TIM3+ CD8+ T cells (Fig. 4d-e and Extended Data Fig. 10h–m).